New radiopharmaceutical for the diagnosis and therapy of prostate cancer: the patent is made in Puglia

The patent for a new radiopharmaceutical for the therapy and diagnosis of prostate cancer in a faster and safer way than current processes is from Puglia. The Molfetta (Bari) company BeForPharma presents the “Psma Cold Kit Shake & Shoot” patent of the new drug at the business expo of the St. Petersburg Economic Forum (Spief).

The company, specialized in radiopharmaceutical research and production, is part of the delegation of Apulian companies participating in the institutional economic mission of the Puglia Region in Russia.

For Puglia, mission to Russia: “Our excellences at the St. Petersburg Economic Forum”

May 29, 2021


“In Puglia – explains the CEO, Roberto La Forgia – with our innovative micro-enterprise, a group of researchers from the Pharmacy Department of the University of Bari and thanks to a regional tender, we have developed an innovative formulation for the diagnosis of prostate cancer, used in the Pet / Ct of medicine nuclear. There are only two other companies in the world that are working on this bio marker, one in the United States and the other in Israel. “

Prostate cancer is among the most frequent malignancies diagnosed in the world in men, only in Italy in 2019 37 thousand new cases were estimated and in Puglia there was an incidence of 111 cases per 100 thousand inhabitants.

PREV Covid vaccinations also open to wedding guests
NEXT TechTalk with Silvia Candiani (Microsoft), the ambition of Italy: business, public administration and citizens